Avid Bioservices Inc. Stock News

Metropolitan Life Insurance Co NY grew its position in shares of Avid Bioservices, Inc. (NASDAQ:CDMO) by 112,775.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 18,060 shares of the biopharmaceutical companys stock after acquiring an additional 18,044 shares during the period. Metropolitan Life Insurance Co NYs holdings []

Amalgamated Bank acquired a new stake in shares of Avid Bioservices, Inc. (NASDAQ:CDMO) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 11,235 shares of the biopharmaceutical companys stock, valued at approximately $288,000. A number of other hedge funds and other institutional investors have also made changes []

Invesco Ltd. lifted its position in Avid Bioservices, Inc. (NASDAQ:CDMO) by 111.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,248,092 shares of the biopharmaceutical companys stock after purchasing an additional 656,730 shares during the quarter. Invesco Ltd. owned 2.04% of []

Royal Bank of Canada lifted its stake in shares of Avid Bioservices, Inc. (NASDAQ:CDMO) by 4,603.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 279,393 shares of the biopharmaceutical companys stock after purchasing an additional 273,453 shares during the quarter. Royal Bank of []

The stock price of Avid Bioservices, a contract development and manufacturing company for biopharmaceutical products, has surged 48% in a month (twenty-one trading days), while it is up a solid 19% in

The stock will be part of a well-known index.

Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well. Here's why.

Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript

Healthcare is one market no one can say is going to slow down, and so, many of the best investments lie within.

Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2021 Results - Earnings Call Transcript

-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --

TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.